VIR 2703
Alternative Names: ALN-COV; VIR-2703Latest Information Update: 01 Mar 2022
At a glance
- Originator Alnylam Pharmaceuticals
- Developer Alnylam Pharmaceuticals; Vir Biotechnology
- Class Antivirals; Small interfering RNA
- Mechanism of Action RNA interference; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued COVID 2019 infections
Most Recent Events
- 23 Feb 2022 Alnylum Pharmaceuticals no longer licensed to Vir Biotechnology
- 23 Feb 2022 Discontinued for COVID-2019 infections (Prevention) in USA (Inhalation), due to the availability of highly effective vaccines and alternative treatment options
- 23 Feb 2022 Discontinued for COVID-2019 infections in USA (Inhalation), due to the availability of highly effective vaccines and alternative treatment options